Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug
December 05, 2019 at 13:54 PM EST
Shares of Biogen rose 4.5% in afternoon trading in response to new data that indicates its recently resurrected experimental Alzheimer’s disease treatment can reduce cognitive decline.